English Deutsch 中文
XinTech
  • Innovative Solutions
  • Expert Support and Knowledge
  • Reliable Cooperation
XinTech
Menu Deutsch 中文

Bayer Builds China Diabetes Portfolio with SciLin Launch

Sep. 2, 2010

On September 3, 2010, Bayer Schering Pharma launched SciLin, the recombinant insulin whose China-marketing rights it bought from Polish Bioton in 2009. Bayer had paid $43.5 million for 15 years of SciLin’s China rights. At the time of the agreement, Bayer forecasted that SciLin should generate between $1.5-2 billion of revenues in China during the term of the agreement.